/Moderna%20Inc%20HQ-by%20hapabapa%20via%20iStock.jpg)
With a market cap of $9.3 billion, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development of messenger RNA (mRNA) therapeutics and vaccines. Known for its COVID-19 vaccine Spikevax, the company also advances treatments across infectious diseases, oncology, and rare diseases, and has formed numerous strategic global partnerships.
Shares of the Cambridge, Massachusetts-based company have significantly underperformed the broader market over the past 52 weeks. Moderna has decreased 80.1% over this time frame, while the broader S&P 500 Index ($SPX) has gained 8.7%. Moreover, MRNA stock has declined 41.5% on a YTD basis, compared to SPX's 4.1% decline.